Cardanol: avaliação toxicogenética e seus efeitos antigenotóxico, antimutagênico e antiapoptótico quando associado à ciclosfosfamida

Abstract

According to the possible antioxidant activity of cardanol about same indication for testing in the field of genetic toxicology and carcinogenesis. Therefore we evaluated the genotoxicity, mutagenicity, the immunomodulatory potential chemopreventive and apoptotic saturated cardanol side chain (2,5, 5 and 10mg/kg), alone and in combination with cyclophosphamide (100mg/kg) in Swiss mice. The results indicated that the cardanol is genotoxic and mutagenic for the lowest and the highest doses tested respectively; and does not stimulate phagocytosis and splenic or apoptosis. However, when associated with cyclophosphamide has antigenotoxic activity, antimutagenic, this being more expressive, and antiapoptotic. Note also that the cardanol associated and / or has low immunomodulatory activity isolated. Thus, it is considered that the cardanol should not be used in association with chemotherapy cyclophosphamide and in particular as a chemotherapeutic adjuvant. However, its low toxicity, suggests its use as a chemopreventive, risk / benefit ratio, demonstrating the therapeutic potential.